INTRODUCTION AND OBJECTIVES: Although quality of life (QOL) is one of the most important considerations in patients treated with anticancer therapies, desirable regimens for neoadjuvant chemotherapy including QOL in locally advanced urothelial carcinoma remain unclear. The present study evaluated the influence of neoadjuvant platinum-based chemotherapy on QOL in patients with locally advanced urothelial carcinoma.
METHODS: Between June 2013 and March 2016, 83 urothelial carcinoma patients who received two courses of neoadjuvant chemotherapy were enrolled in this prospective observational study. Neoadjuvant regimens included gemcitabine+cisplatin (GCis) or gemcitabine+carboplatin (GCb) therapies. As a primary endpoint, we assessed QOL changes in each group before and after chemotherapy using the QLQ questionnaire on days 1, 3, and 15 of each cycle. Secondary endpoints included toxicity, safety, weight loss, renal function decline, and tumor responses.
RESULTS: QOL analyses were performed in 39 patients receiving GCis and in 44 patients receiving GCb. The QOL items appetite loss, role functioning, nausea/vomiting, physical, and fatigue deteriorated >10% from baseline in the GCis group but not in the GCb group. Constipation worsened, whereas scores for pain and emotional items improved in both groups. Objective response rates were 38.5% and 43.2% in the GCis and GCb groups, respectively. CONCLUSIONS: Both GCis and GCb regimens were feasible in terms of QOL. The GCb regimen may be associated with a better QOL status especially in regard to gastrointestinal symptoms.
Source of Funding: none

MP86-07 REDUCTION OF SKELETAL MUSCLE INDEX AS A PREDICTIVE FACTOR IN PATIENTS WITH UROTHELIAL CARCINOMA
Takashi Nagai*, Anjo, Japan; Taku Naiki, Keitaro Iida, Toshiki Etani, Ryosuke Ando, Noriyasu Kawai, Nagoya, Japan; Hidetoshi Akita, Takehiko Okamura, Anjo, Japan; Takahiro Yasui, Nagoya, Japan INTRODUCTION AND OBJECTIVES: The progression of cancer leads to metabolic disorders and malnutrition, which results in the loss of skeletal muscle mass (sarcopenia). Sarcopenia is an objective indicator of cancer cachexia, and has been previously e1158 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 reported as a predictor of hospitalization, postoperative complications as well as survival in cancer patients.Herein, we analyzed the changes in skeletal muscle mass during chemotherapy using computer tomography (CT) images, and verified whether sarcopenia is a predictive factor of overall survival (OS) or performance status (PS) deterioration. METHODS: We retrospectively reviewed patients with urothelial carcinoma (UC) who had received cisplatin-based chemotherapy as first line and GD (Gemicitabine plus Docetaxel) chemotherapy as second line treatment regimens between 2006 and 2015 in our hospital. Skeletal muscle area (SMA) at the third lumbar vertebrae was measured using CT images. Based on these data, we calculated skeletal muscle index (SMI ¼ SMA/height2), and defined the changes in SMI for months between two points as DSMI (DSMI ¼ SMI/duration). We verified the relationships among DSMI, OS and PS. Mann-Whitney U test, t-tests, Kaplan-Meier method and Log-rank test were used to analyze the data.
RESULTS: This study included data from 55 UC patients. Due to lack of CT data, 20 patients were excluded at first line and 6 patients were excluded at second line. Median DL3 SMI during the first 2 cycles of first line chemotherapy was -1.66 (range, -5.92-1.62), and median DL3 SMI during the first 2 cycles of second line treatment was 0.042 (range, -1.10-7.42). The PS tended to deteriorate in patients when DL3 SMI was high during the first and second line treatments. By setting a cut-off value of DL3 SMI during the first 2 cycles of the first and second line regimen as -0.1 (first line) and -1 (second line), the Kaplan-Meier log rank analysis showed that patients in high DL3 SMI group (first line:< -0.1, second line< -1) had poorer OS when compared with those in the low DL3 SMI group (fist line: -0.1, second line: -1; P < 0.01; Figure) CONCLUSIONS: It is possible to predict OS and PS deterioration in chemotherapy-treated UC patients by measuring DL3 SMI and setting proper cutoff of DL3 SMI. Thus, reduction of skeletal muscle mass may be considered as a useful predictor of prognosis in these patients.
Source of Funding: none
MP86-08 USE OF A MOBILE APP FOR ECOLOGICAL MOMENTARY ASSESSMENT OF PAIN AND OTHER SYMPTOMS IN PATIENTS WITH UROLOGIC CHRONIC PELVIC PAIN SYNDROME
James Griffith*, Chicago, IL; Ted Herman, Anthony Andrys, Iowa City, IA; Michael Bass, Bayley Taple, Brett Lloyd, Chicago, IL; Bradley Erickson, Iowa City, IA INTRODUCTION AND OBJECTIVES: Pain in patients with chronic pelvic pain varies widely by location, intensity, severity and by its intermittency. Static assessment of pain does not allow for a comprehensive description of this inherent heterogeneity of pain, potentially obscuring phenotypic differences in UCPPS patients that could help predict treatment response and disease course. Ecological Momentary Assessment (EMA) of pain is a way to describe pain more comprehensively. Mobile apps can communicate directly with patients at all times of the day in most locations and are thus, perfectly suited to collect EMA pain data. For the Multidisciplinary Approach to Pelvic Pain (MAPP) Research Network, we developed a mobile app to capture pain and associated symptoms in a time-efficient manner. We present the results from the app beta testing herein. We hypothesized that participants would find the app easy to use and that utilization of the app would reveal significant daily pain variability.
METHODS: A total of 22 participants completed beta testing for 14 days, locating and rating their pain and other symptoms. Mobile phone notifications that linked to and opened the app were sent at wake up, 4 and 8 hours after wake-up and bedtime. On Day 15 participants completed the NASA task load index to assess app usability and satisfaction. Participants then completed a qualitative exit interview to give us feedback on all aspects of the app and testing. Thus, we obtained both quantitative and qualitative information during the betatesting period.
RESULTS: We created a summary score for pain using the maximum pain rating across different areas of the body at a particular time. Using a linear model with time of day, nested with testing day, we found that pain varied significantly during the day, F (37, 257) ¼ 1.75, p ¼ .007. Qualitative interviews and App ratings (see figure) suggested that the app was simple and easy to use (e.g. low mental demand, high app compliance) CONCLUSIONS: Our quantitative and qualitative results show that our app is easy to use for participants and is able to capture intraday variability in pain across multiple areas of the body. Moreover, our participants indicated that they would be willing to use this app going forward both for research and clinical/treatment purposes. Mobile apps appear to be well-suited to study chronic urologic conditions. Utilization of the app for EPA testing is currently underway within the MAPP Research Network. 
Source of
INTRODUCTION AND OBJECTIVES: The American Urological
Association Symptom Score (AUA-SS) has been the gold standard for assessing lower urinary tract symptoms (LUTS); however, it is frequently incorrectly completed or unfinished due to inadequate literacy/numeracy. We developed the novel FLOW questionnaire to assess LUTS regardless of respondents' literacy/numeracy level. We previously showed the FLOW questionnaire is internally consistent and rapidly administered. Our current study objective is to establish criterion
